When Does Acceptable Become Unacceptable? Toxicities of Emerging Therapies [0.03%]
当正常变成不正常？新兴疗法的毒性问题
Sydney Barned,Lucie Heinzerling,Lauren A Dalvin
Sydney Barned
Novel systemic anticancer therapies, including immune checkpoint inhibitors (ICIs), antibody-drug conjugates (ADCs), bispecific antibodies, and next-generation targeted agents, have improved survival, expanded into earlier disease settings,...
Advancing Antibody-Drug Conjugates: Current Perspectives and Future Directions [0.03%]
抗体偶联药物的现状及未来展望
Julian David Etessami,Carmine Valenza,Anthony W Tolcher et al.
Julian David Etessami et al.
Antibody-drug conjugates (ADCs) have rapidly emerged as one of the most transformative therapeutic agents in modern oncology. Their rational design enables selective drug delivery to tumor cells while limiting systemic exposure, resulting i...
Translating Innovation Into Practice: Dissemination of Immune Checkpoint Inhibitors and Their Toxicity Management Across the Globe [0.03%]
创新实践：免疫检查点抑制剂的全球推广及其毒性管理
Mehak Trikha,Susan Dent,Kaysia Ludford et al.
Mehak Trikha et al.
Immune checkpoint inhibitors (ICIs) have redefined the therapeutic landscape of oncology, producing durable responses across multiple tumor types and treatment settings. However, widespread adoption of ICIs has introduced challenges related...
Noah Richardson,Alok K Tewari,Patrizia Giannatempo et al.
Noah Richardson et al.
Male germ cell tumors, of which testicular is the most common, are rare but generally highly curable malignancies. Cure rates in the metastatic setting are among the highest for any solid tumor, although outcomes in the poor-risk subgroup r...
Stuart M Lichtman
Stuart M Lichtman
Older adults account for approximately 60% of new cancer diagnoses and 70% of cancer-related deaths, yet they remain consistently under-represented in clinical trials and are routinely assessed using performance status (PS) tools developed ...
Optimizing Breast Cancer Survivorship: Addressing Lifestyle, Weight Management, and Psychological Health [0.03%]
优化乳腺癌幸存者的生活方式、体重管理和心理健康的策略
Jasmin Hundal,Jane Chen,K Brooke Russell et al.
Jasmin Hundal et al.
With more than 4 million breast cancer (BC) survivors in the United States, oncologic care has expanded to encompass the long-term health, physical function, and quality of life of this growing population. Cancer survivorship is an active, ...
Improving Affordability in Cancer Care for Resource-Limited Settings: Highlights From JCO Global Oncology [0.03%]
改善资源匮乏地区癌症治疗的可负担性：JCO全球肿瘤学亮点
Long Thanh Nguyen,Celine Hoyek,Akhil Kapoor et al.
Long Thanh Nguyen et al.
By 2045, more than three quarters of global cancer deaths are projected to occur in low- and middle-income countries (LMICs); however, the global availability of cancer care remains constrained by high costs and inequitable access. Value-ba...
Translating Cancer Science Into Cancer Care: Using Serious Illness Communication Frameworks to Deliver High-Quality Person-Centered Care in Neuro-Oncology [0.03%]
转化癌症科学以改善癌症护理：使用严重的疾病交流框架来提供高质量的以患者为中心的神经肿瘤科护理
Heather E Leeper,Kathy Oliver,Helen Bulbeck et al.
Heather E Leeper et al.
People with CNS cancer and their caregivers need and deserve not only innovative cancer-directed care but also high-quality person-centered care for navigating living their lives in the face of their cancer diagnosis and treatment. Palliati...
Unique Considerations in Rare Gynecologic Tumors: Gestational Trophoblastic Neoplasia, Germ Cell Tumors, and Clear Cell Ovarian Cancers [0.03%]
罕见妇科肿瘤的特殊考虑因素：妊娠滋养细胞肿瘤、生殖细胞肿瘤和透明细胞卵巢癌
John H Farley,Keiichi Fujiwara,Jung Yun Lee et al.
John H Farley et al.
Rare cancers are usually defined as an incidence of
Evolving Paradigms in the Treatment of Philadelphia Chromosome-Positive ALL [0.03%]
阳性Ph-like基因重排ALL的治疗新理念
Nicholas J Short,Josep-Maria Ribera,Iman Abou Dalle et al.
Nicholas J Short et al.
The treatment of adults with Philadelphia chromosome-positive ALL (Ph+ ALL) has evolved significantly over the past 25 years. These changes have been driven largely by the development of potent BCR::ABL1 tyrosine kinase inhibitors (TKIs) su...